Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo

@article{Eglen1995PharmacologicalCO,
  title={Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo},
  author={R. Eglen and C. Lee and W. Smith and L. Johnson and R. Clark and R. Whiting and S. Hegde},
  journal={British Journal of Pharmacology},
  year={1995},
  volume={114}
}
1 The pharmacological effects in vivo, of RS 25259‐197, a selective 5‐HT3 receptor antagonist, have been investigated. 2 In anaesthetized rats, RS 25259‐197, administered by the intravenous, intraduodenal or transdermal route, dose‐dependently inhibited the von Bezold‐Jarisch reflex induced by 2‐methyl 5‐HT (ID50 = 0.04 μg kg−1, i.v., 3.2 μg kg−1, i.d. and 32.8 μg per chamber, respectively). In this regard, when administered intraduodenally, RS 25259‐197 was more potent and exhibited a longer… Expand
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro
Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats.
The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro
Neuropharmacology of emesis in relation to clinical response.
Ondansetron and related 5-HT3 antagonists: recent advances.
Antagonism of cisplatin induced emesis in the dog.
...
1
2
3
...